Results 61 to 70 of about 2,744,211 (203)

Alterations of bone proteins in medication‐related osteonecrosis of the jaw

European Journal of Oral Sciences, Volume 133, Issue 2, April 2025.
Abstract Changes in the protein expression pattern of osteoblastic lineage cells from the alveolar bone (OLAB) during medication‐related osteonecrosis of the jaw (MRONJ) have rarely been investigated. This lack of information is partly because of the limited availability of healthy samples and the lack of human alveolar bone cell lines for research ...
Andrea Schubert, Phillipp Brockmeyer, Philipp Kauffmann, Jan Wiegel, Florian Lautenbacher, Nicolai Miosge, Boris Schminke   +6 more
wiley   +1 more source

Study of Adverse Effect Profile of Parenteral Zoledronic Acid in Female Patients with Osteoporosis [PDF]

Journal of Clinical and Diagnostic Research, 2016
Introduction: Osteoporosis is still a under recognized entity in the population. Osteoporosis-related fractures can be prevented if people at risk can be screened, diagnosed and treated early.
Prem Kotian, Archith Boloor, Sushanth Sreenivasan   +2 more
doaj   +1 more source

Hypophosphataemia in adults: approach to diagnosis and management

Internal Medicine Journal, EarlyView.
Abstract Hypophosphataemia is a common electrolyte disorder which can have clinically significant consequences for bone, muscle, neurological and haematological function. Its causes range from transient transcellular shifts in hospitalised patients to chronic renal phosphate‐wasting disorders mediated by fibroblast growth factor 23 (FGF23).
Kajanan Parameshwaran, Mawson Wang, Kirtan Ganda   +2 more
wiley   +1 more source

Once-yearly zoledronic acid in hip fracture prevention

, 2009
Oddom Demontiero, Gustavo DuqueAging Bone Research Program, Nepean Clinical School, University of Sydney, Penrith, NSW, Australia; Department of Geriatric Medicine, Nepean Hospital, Penrith, NSW, AustraliaAbstract: Osteoporosis is an escalating global ...
Demontiero, O, Oddom Demontiero, Duque, G, null Demontiero, Gustavo Duque   +4 more
core   +1 more source

Acute unilateral anterior uveitis following zoledronic acid infusion: A case report

SAGE Open Medical Case Reports, 2020
Bisphosphonates are widely used to treat several clinical conditions. Zoledronic acid is one of this class, commonly used for the treatment and prevention of osteoporosis, hypercalcemia of malignancy, Paget’s disease, and multiple myeloma.
Kiruththihan Anandasayanan, Muthusamy Malaravan, Navaneethakrishnan Suganthan   +2 more
doaj   +1 more source

Osteoporosis and Periodontitis: Two‐Way Epidemiological and Mechanistic Evidence

Journal of Periodontal Research, EarlyView.
This review investigates the main mechanistic pathways connecting local periodontitis to systemic osteoporosis. Seven interconnected mechanisms are identified. ABSTRACT Osteoporosis and periodontitis are highly prevalent, chronic inflammatory diseases that constitute a major global health burden.
Jia Chang, Geeta Madhuri Bhuvanagiri, Megan Dulkanchainun, Cunyu Wang   +3 more
wiley   +1 more source

Endocytotic uptake of zoledronic acid by tubular cells may explain its renal effects in cancer patients receiving high doses of the compound.

PLoS ONE, 2015
Zoledronic acid, a highly potent nitrogen-containing bisphosphonate used for the treatment of pathological bone loss, is excreted unmetabolized via the kidney if not bound to the bone.
Anja Verhulst, Shuting Sun, Charles E McKenna, Patrick C D'Haese   +3 more
doaj   +1 more source

Combined Effects of Romosozumab and Zoledronate on the Development of Osteonecrosis of the Jaw

Oral Diseases, EarlyView.
ABSTRACT Objective This study aimed to assess the occurrence of medication‐related osteonecrosis of the jaw (MRONJ) in mice following the sequential administration of romosozumab and zoledronate and to confirm their inhibitory effects on osteoclast differentiation in vitro.
Hae‐Seo Park, Shihyun Kim, Seo‐Yeong An, Reuben H. Kim, Jongho Choi, Moon‐Young Kim   +5 more
wiley   +1 more source

Algorithm for Surgical Management in Patients in Treatment With Medication Associated With Osteonecrosis of the Jaws

Oral Surgery, EarlyView.
ABSTRACT Background Osteonecrosis of the jaws is associated with various drugs, including antiresorptives such as bisphosphonates and denosumab, as well as antiangiogenics. These drugs are used for the treatment of multiple diseases, notably osteoporosis, bone metastases, Paget's disease, osteogenesis imperfecta, malignant hypocalcaemia, among others ...
Rodríguez Naranjo Julia Alexandra, Gómez Hernández Kevin Andrew, Cabrera del Cid María Fernanda, Jerez Robalino James Philippe   +3 more
wiley   +1 more source

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial

Journal of Bone Oncology, 2019
Background: Although denosumab has been approved as an antiresorptive agent for giant cell tumor of bone, its efficacy has not been proven. Objectives: To compare the efficacy and safety of denosumab and zoledronic acid treatment in patients with ...
Shenglong Li, Peng Chen, Qiankun Yang
doaj   +1 more source